Home‎ > ‎

Work Packages

Programme activities have been split into 3 work packages:

Work Package 1 (EPI-MEL): Identification and validation of an epigenetic biomarker panel with the potential to develop a clinically relevant in vitro diagnostic assay

The first goal is to validate an epigenomic signature initially identified in the FP7-funded programme, TargetMelanoma (www.targetmelanoma.com). Validation of a protein panel of epigenetically regulated biomarkers that can better determine melanoma outcome (prognosis) than currently used parameters, which can then be further developed into a clinically applicable molecular diagnostic with commercial viability.


Work Package 2 (APO-MEL): Identification and validation of an apoptotic biomarker panel with the potential to develop a clinically relevant in vitro predictive assay for DTIC treatment

The second goal is to utilize in vitro analysis of apoptotic pathways with the assistance of a novel systems biology approach, which incorporates mathematical systems modelling, quantitative biochemistry and cell biology, to generate an in silico modelling system to predict patient responses to decarbazine (DTIC).


Work Package 3 (PREX-MEL): Development of a model of PREX signalling-mediated melanoma cell migration and invasion, and identification and validation of an associated biomarker panel with the potential to develop a clinically relevant in vitro diagnostic assay

The third goal is to investigate components of the P-Rex1 pathway that drive migration of melanoblast and progression of metastasis, incorporating a computational system tailored to model complex signalling pathways.